Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

December 9, 2022

Study Completion Date

March 10, 2023

Conditions

Safety IssuesEfficacy, Self

Interventions

DRUG

Béfizal

600 mf befizal a day for one year

Trial Locations (1)

HEGP Hospital, Paris

All Listed Sponsors

collaborator

European Georges Pompidou Hospital

OTHER

collaborator

CLAIROP

UNKNOWN

lead

Hôpital Necker-Enfants Malades

OTHER

NCT04561466 - Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy | Biotech Hunter | Biotech Hunter